Issue 7 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

32

No.

7

July 31, 2009Jul 31, 2009

Free

DOWNLOAD THE PDF

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer

Shorter, Simpler Consent Form Proposed For Phase I Trials

How Much Is Life Worth? The $440 Billion Question

Sunitinib Prolongs Survival In Poor Prognosis, Study Finds

Breast MRI Recipients More Likely To Choose Mastectomy

Opioid Pain Reliever Approved With Risk Reduction Plan

NCI Cooperative Group Clinical Trials Approved

Recent Issues

Volume 52 | Issue 30 - July 31, 2026

Volume 52 | Issue 29 - July 24, 2026

Volume 52 | Issue 28 - July 17, 2026

Volume 52 | Issue 27 - July 10, 2026

Volume 52 | Issue 26 - July 02, 2026

Volume 52 | Issue 25 - June 26, 2026